PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.

PCRX shareholders will receive just $36.50 per share in cash, representing an aggregate equity value of $1.65 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers

CLICK HERE TO JOIN

MILWAUKEE, Oct. 8, 2026 /PRNewswire/ -- Ademi LLP is investigating whether the proposed acquisition of Pacira (NASDAQ: PCRX) by Viatris, provides fair value to Pacira's public shareholders and whether Pacira's Board adequately protected shareholder interests in negotiating and approving the transaction.

Are You a PCRX Shareholder?

If you own Pacira shares, Ademi LLP would like to hear from you about the proposed acquisition and your rights as a shareholder.

You may also contact Guri Ademi at [email protected] or toll-free at 866-264-3995. There is no cost or obligation to you.

What Is Ademi LLP Investigating?

The exchange ratio and whether it adequately reflects Pacira's value and future prospects;

Substantial change-of-control benefits available to Pacira insiders in connection with the transaction;

Restrictions on competing transactions, including a significant termination penalty that may discourage another potential buyer from making a superior proposal; and

The conduct of Pacira's Board of Directors in negotiating and approving the transaction and whether the Board fulfilled its duties to public shareholders.

What Should PCRX Shareholders Do?

Contact Ademi LLP to discuss your rights and our investigation. There is no cost or obligation to you.

Guri AdemiAdemi LLP

Toll Free: (866) 264-3995

Email: [email protected]

About Ademi LLP

Ademi LLP represents investors in shareholder litigation involving mergers, acquisitions, buyouts, and individual shareholder rights.

Attorney advertising. Prior results do not guarantee similar outcomes.

SOURCE Ademi LLP